Ranibizumab has proven to be of benefit to improve the perfusion in the retina of patients with Choroidal Melanoma. The investigators consider that higher doses of Ranibizumab can help reduce the number of laser treatments that might be needed to control the tumor.

Inclusion Criteria:

• 18 years or older
• Primary pigmented or amelanotic choroidal melanoma measuring 16 mm or less in the largest basal diameter and 6 mm or less in the apical height.
• Location of the tumor, posterior to the equator of the eye.
• Documented growth of tumor by A-B scan.
• Ability to provide written informed consent and comply with the study assessment for the full duration of the study.

Exclusion Criteria:

• Pregnancy or lactation.
• Premenopausal women not using adequate contraception.
• Current infection or inflammation in either eye.
• Extension of tumor into the orbit.
• Regional spread or metastatic disease.
• Any other condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated.
• Any known allergy to any of the components to be used in the study.
• Participation in another simultaneous medical investigation or trial.

Adverse event data are not available to be reported per group or according to severity because the PI left the institution and adverse event data in the required format is not available.